ARS Pharmaceuticals Inc expected to post a loss of 13 cents a share - Earnings Preview

* ARS Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on August 8 (estimated) for the period ending June 30 2024

* The San Diego California-based company is expected to report a 9,900.0% increase in revenue to $1 million from $10 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for ARS Pharmaceuticals Inc is for a loss of 13 cents per share.

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts had risen by about 32.4% in the last three months. ​

* Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $19.00​, above​ its last closing price of $8.80. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Mar. 31 2024 -0.12 -0.11

Dec. 31 2024 -0.11 -0.14 -0.07 Beat 50

Sep. 30 2023 -0.19 -0.18 -0.16 Beat 12.4​

Jun. 30 2023 -0.19 -0.17 -0.18 Missed -3.6

​​Mar. -0.17 -0.17 -0.16 Beat 4.6

31 2023

Dec. 31 2022 -0.13 -0.13 0.77 Beat 692.3​

Sep. 30 2022 -0.35 -0.35 -0.50 Missed -40.8

Jun. 30 2022 -0.50 -0.48 -0.55 Missed -13.8

This summary was machine generated May 10 at 11:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)